Welcome to our dedicated page for Absci news (Ticker: ABSI), a resource for investors and traders seeking the latest updates and insights on Absci stock.
Absci Corp (ABSI) combines generative AI with synthetic biology to accelerate therapeutic discovery. This news hub provides investors and industry professionals with essential updates on the company's advancements in AI-driven drug development, strategic collaborations, and platform innovations.
Access verified press releases covering key milestones including research breakthroughs, partnership announcements, and financial developments. Our curated collection enables efficient tracking of Absci's progress in optimizing biologic drug creation through its Integrated Drug Creation™ platform.
Explore updates across critical categories: AI technology enhancements, pharmaceutical partnerships, therapeutic pipeline developments, and financial performance. Each update maintains factual accuracy while highlighting Absci's unique position at the intersection of computational biology and drug discovery.
Bookmark this page for direct access to primary source materials and official announcements. Regularly updated content ensures stakeholders stay informed about Absci's contributions to oncology, immunology, and next-generation biologic therapies.
Absci Corporation (Nasdaq: ABSI) reported transformative results for 2022, achieving industry breakthroughs in drug development using generative AI. Key highlights include:
- Revenue rose to $5.7 million from $4.8 million year-over-year.
- R&D expenses increased to $58.9 million, reflecting enhanced platform capabilities.
- Net loss reduced to $104.9 million from $101.0 million.
- Cash reserves as of December 31, 2022, totaled $164.4 million.
Looking forward, Absci expects to add at least ten new active programs in 2023, enhancing its partnerships and cash flow.
Absci Corporation (Nasdaq: ABSI) announced its participation in the B. Riley Securities' Life Sciences Tools Conference on April 6, 2023. The event focuses on integrating AI and proteomics into drug discovery. Absci’s management will engage in a panel discussion at 7:30 a.m. PT and a fireside chat at 12:30 p.m. PT. Interested parties can access the live webcast by registering through the conference's website. Absci specializes in generative AI drug creation, aiming to expedite the development of biologics and enhance therapeutic benefits through its Integrated Drug Creation™ platform.
Absci Corporation (Nasdaq: ABSI) recently announced its participation in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum scheduled for March 21, 2023, at 3:00 p.m. Eastern Time. This virtual event will feature a fireside chat with Absci management, providing insights into the company's innovative generative AI drug creation technologies.
Absci leverages AI alongside advanced wet lab methods to accelerate drug development, enhancing the probability of success by optimizing various drug characteristics. Interested parties can stream the event live via the company's investor relations website.
Absci Corporation (Nasdaq: ABSI) has expanded into the European pharmaceutical market by launching its Innovation Center in Zug, Switzerland. This strategic move aims to enhance its R&D portfolio and drug development pipeline. The company has appointed two senior executives, Christine Lemke and Christian Stegmann, to spearhead its initiatives. Lemke brings extensive experience from major global biopharmaceutical companies, while Stegmann has a strong background in R&D leadership. The Zug Innovation Center positions Absci to leverage European biotech resources and talent, underscoring its commitment to delivering innovative therapies using generative AI.
Absci Corporation (Nasdaq: ABSI), a leader in generative AI drug creation, announced their participation in the 43rd Annual Cowen Health Care Conference. The management team will engage in a panel discussion on March 6 at 1:40 PM PT and a fireside chat on March 8 at 9:50 AM PT. Both sessions will be accessible via a live and archived webcast on the company’s investor relations website. Absci utilizes its Integrated Drug Creation™ platform to enhance drug development, allowing rapid transitions from AI-designed antibodies to lab-validated candidates within weeks. The company aims to revolutionize the delivery of therapeutics globally.
Absci Corporation (Nasdaq: ABSI) has partnered with St. John’s Cancer Institute (SJCI) to accelerate cancer therapy development.
This collaboration utilizes Absci’s Integrated Drug Creation platform and SJCI’s extensive cancer biospecimen database to streamline the identification of new therapeutic candidates.
The initial focus will be on urological and gastrointestinal cancers, aiming to significantly reduce the typical decade-long drug development timeline and high costs.
Experts from both organizations express optimism that this partnership will enhance the discovery of effective cancer treatments.
Absci Corporation (Nasdaq: ABSI) has expanded its Scientific Advisory Board by adding three prominent experts: Dr. Victor Greiff, Dr. Timothy Lu, and Dr. Hubert Truebel, aiming to enhance its leadership in biologic drug creation. Dr. Greiff specializes in in silico antibody design, Dr. Lu focuses on synthetic biology, and Dr. Truebel brings extensive experience in translational medicine. This strategic move aligns with Absci's mission to leverage generative AI and wet lab technologies to expedite drug development. The company intends to innovate faster and improve therapeutic success rates through this strengthened team.
Absci Corporation (Nasdaq: ABSI) announced a significant breakthrough in biotech by using zero-shot generative AI to create and validate de novo antibodies in silico. This advancement could reduce the time for drug leads to enter clinical trials from six years to just 18-24 months while increasing their success probability. Traditionally, drug discovery is costly and lengthy, taking over a decade and more than $1 billion. Absci's innovative approach may unlock treatments for undruggable diseases and enhance biologic drug discovery efficiency.
Absci Corporation (Nasdaq: ABSI) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on January 12th at 8:15 a.m. PT. The event can be accessed via a live and archived webcast on the company's investor relations website.
Absci is focused on generative AI drug discovery, utilizing deep learning and synthetic biology to create innovative biotherapeutics. Their Integrated Drug Creation™ platform enables the identification of new drug targets and the development of protein-based drugs.
Absci Corporation (Nasdaq: ABSI) announced its participation in the Berenberg Discover AI Seminar on November 29, 2022, at 10:00 a.m. Eastern Time, in New York. The company, a pioneer in generative AI drug creation, will engage in a fireside chat during the event. Absci focuses on drug and target discovery using deep learning AI and synthetic biology to produce innovative protein-based therapeutics. Their Integrated Drug Creation™ platform streamlines the process from identifying drug targets to generating manufacturing cell lines.
FAQ
What is the current stock price of Absci (ABSI)?
What is the market cap of Absci (ABSI)?
